NISOLDIPINE

Post-LOESM

nisoldipine

Viatris (2)

ANDAORALTABLET, EXTENDED RELEASE

Approved

Jul 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NISOLDIPINE (nisoldipine) by Viatris (2) is calcium channel antagonists [moa]. Approved for hypertension. First approved in 2008.

Drug data last refreshed 19h ago

Mechanism of Action

Calcium Channel Antagonists

Pharmacologic Class:

Dihydropyridine Calcium Channel Blocker

Indications (1)

hypertension

Clinical Trials (1)

NCT00311870Phase 4Completed

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Started Mar 1993

52 enrolled

Diabetic Nephropathy

Company

Worked on NISOLDIPINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.